Cancer treatment firm Sirtex Medical said that dose sales of its SIR-Spheres yttrium-90 (Y-90) resin microspheres in the Americas region grew more than 28% over the same period a year ago.
During the six-month period (end-December 31, 2014), the company supplied 3,390 doses. Regional gross sales were $54.3 million, up 36.7% over the $39.8 million generated in the first half of the prior fiscal year. Sirtex said it sold 4,950 doses worldwide in the first six months of the fiscal year, representing 26.3% growth versus the same period last year.
Sirtex attributed the performance to increased awareness and customer education.
